利福昔明与双歧杆菌三联活菌胶囊序贯疗法治疗小肠细菌过度生长的效果分析

Efficacy of rifaximin and bifidobacterium triple viable capsules sequential therapy for small intestinal bacterial overgrowth

目的探讨利福昔明与双歧杆菌三联活菌胶囊序贯疗法治疗小肠细菌过度生长的效果。方法选择2013年1月-2015年1月在我院就诊的78例小肠细菌过度生长患者作为研究对象,随机分为观察组和对照组各39例,观察组接受14 d利福昔明与14 d双歧杆菌三联活菌胶囊序贯治疗,对照组仅接受14 d利福昔明治疗,比较两组疗效。结果观察组与对照组小肠细菌过度生长阳性者转阴率(76.92%vs 53.84%)存在统计学差异(P<0.05);两组临床症状治疗有效率(64.10%vs53.85%)存在统计学差异(P<0.05)。结论利福昔明与双歧杆菌三联活菌胶囊序贯治疗小肠细菌过度生长效果明显。

Objective To investigate the treatment efficacy of rifaximin and bifidobacterium triple viable capsules sequential therapy for small intestinal bacterial overgrowth（SIBO）. Methods From January 2013 to January 2015, 78 patients with SIBO in our hospital were chosen as research objects. All patients were randomly divided into observation group（n=39） and control group（n=39）, and the observation group received rifaximin and bifidobacterium triple viable capsules sequential therapy for 14 days, while the control group received 14 days of rifaximin alone treatment. After treatment, the differences of curative effect between two groups were compared. Results The differences of turning-negative rate of SIBO between observation group and control group had statistical significance（76.92% vs 53.84%, P〈 0.05）. There was statistically significant difference of treatment efficiency between observation group and control group（64.10% vs 53.85%, P〈 0.05）. Conclusion The efficacy of rifaximin and bifidobacterium triple viable capsules sequential therapy for SIBO is obvious.